Naik Rajashri R, Shakya Ashok K
Department of Biopharmaceutics and Clinical Pharmacy, Pharmacological and Diagnostic Research Center, Al-Ahliyya Amman University, Amman, Jordan.
Department of Pharmaceutical Sciences, Pharmacological and Diagnostic Research Center, Al-Ahliyya Amman University, Amman, Jordan.
Front Mol Biosci. 2021 Feb 4;7:636738. doi: 10.3389/fmolb.2020.636738. eCollection 2020.
Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 are trying to content the virus by isolating the patients and treating them with the approved antiviral that have been previously used in treating SARS, MERS, and drugs that are used to treat other viral infections. Some of these are under clinical trials. At present there are no therapeutically effective antiviral present and there are no vaccines or drugs available that are clinically approved for treating the corona virus. The current strategy is to re-purpose the available drugs or antiviral that can minimise or reduce the burden of the health care emergencies. In this article the reuse of antiviral, US-FDA approved drugs, plant based therapeutic, anti-malarial, anti-parasitic, anti-HIV drugs and the traditional medicines that are being currently used in treating the symptoms of COVID-19 patients is discussed emphasis is also given on the treatment using monoclonal antibodies. The present article provides the therapeutic strategies that will qualify as one of the best available treatment for the better management of the COVID-19 patients in order to achieve medical benefits.
自2019年12月以来,新型冠状病毒SARS-CoV-2(新冠病毒)已在全球引发大流行,病例数和患者死亡人数不断上升。绝大多数应对新冠病毒活跃病例增加和患者死亡的国家,都在试图通过隔离患者并用先前用于治疗SARS、中东呼吸综合征的已获批抗病毒药物以及用于治疗其他病毒感染的药物来对抗这种病毒。其中一些药物正在进行临床试验。目前尚无治疗有效的抗病毒药物,也没有临床批准用于治疗新冠病毒的疫苗或药物。当前的策略是重新利用现有的药物或抗病毒药物,以尽量减少或减轻医疗紧急情况的负担。本文讨论了目前用于治疗新冠患者症状的抗病毒药物、美国食品药品监督管理局(US-FDA)批准的药物、植物性疗法、抗疟疾药物、抗寄生虫药物、抗艾滋病毒药物以及传统药物的再利用,还重点介绍了单克隆抗体治疗。本文提供了一些治疗策略,这些策略将成为对新冠患者进行更好管理以实现医疗效益的最佳可用治疗方法之一。